Cell Therapeutics, Inc.
Investigational Studies Highlight Potential Utility of Zevalin Ibritumomab Tiuxetan Radioimmunotherapy in Stem Cell Transplantation for Non-Hodgkin's Lymphoma
Published in Blood Weekly, June 19th, 2008
At the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO), two studies were presented investigating the potential utility of Zevalin(R) (Ibritumomab Tiuxetan) radioimmunotherapy as replacement for external beam radiations or supplement to high-dose chemotherapy in the treatment of non-Hodgkin's lymphoma (NHL). Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTA) markets Zevalin in the United States.
"These two studies add to the increasing body of data suggesting that radioimmunotherapy may be a useful adjunct to stem cell transplantation in late stage non-Hodgkin's lymphoma. It appears not to delay engraftment or add substantially to the toxicities of...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2008-06-19)
More Articles from Blood Weekly
- McGill University Health Centre
Hip and knee replacement patients not receiving treatment to reduce blood clot risk - Research
Policy environments may shape international progress of human embryonic stem cell research - Alpha-thalassemia
New alpha-thalassemia findings from Mahidol University published - Angiotensins
Study data from M.A. Richardson et al provide new insights into angiotensins - Breast Cancer
Researchers from University of Indianapolis report recent findings in breast cancer - Cell Therapeutics, Inc.
Novel Investigational Regimen Combining Radiation Enhancing Agent With Ibritumomab Tiuxetan Zevalin Produces High Rate of Complete Responses in Patients With Rituximab-Refractory Follicular Non-Hodgkin's Lymphoma - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
